Dehydroepiandrosterone Administration in Treating Medical and Neuropsychiatric Disorders

Ritsner, Michael S.

doi:10.1007/978-1-4020-6854-6_17

Search citation statements

Order By: Relevance

Paper Sections

Select...

Treatment1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DHEA augmentations (50–200 mg/day) for a period of 1–12 weeks were examined in cross‐sectional [69–71] and crossover [72–74] designs. Comparative analyses of the obtained findings are presented in the review [75]. Table 1 presents the main parameters and results from clinical trials with DHEA and PREG augmentations.…”

Section: Treatmentmentioning

confidence: 99%

Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials

Ritsner

2010

CNS Neuroscience & Therapeutics

Self Cite

View full text Add to dashboard Cite

Neurosteroids, such as pregnenolone (PREG), dehydroepiandrosterone (DHEA), and their sulfates (PREGS and DHEAS) are reported to have a modulatory effect on neuronal excitability and synaptic plasticity. They also have many other functions associated with neuroprotection, response to stress, mood regulation, and cognitive performance. Furthermore, these neurosteroids have been linked to, and their levels are altered in, neuropsychiatric disorders. This review highlights what is currently known about the metabolism and mode of action of PREG and DHEA, as well as about alterations of these neurosteroids in schizophrenia. This review also provides substantial information about clinical trials with DHEA and PREG augmentation with of antipsychotic agents in schizophrenia.

show abstract

Section: Treatmentmentioning

confidence: 99%